Objective: To examine the outcome, including overall and cause-specific mortality, of PD patients subsequent to 10 years of surveillance in Shanghai, China. This is an extension study of our previous investigation on mortality.

Background: Standardized mortality ratio (SMR) is the most frequently used index in Parkinson’s disease (PD) survival survey. However, there is little SMR data in PD from China.

Methods: One hundred fifty-seven PD patients recruited from the movement disorder clinic of Rui Jin Hospital in 2006 were followed up until December 31, 2016 or death, representing a follow-up period of up to 10 years. Overall and cause-specific standardized mortality ratios (SMR) were calculated, and predictors for survival at disease onset were estimated.

Results: Thirty one patients had died by December 31, 2016, and the SMR at 10 years of follow-up was 0.87 (0.59-1.25). The primary direct cause of death was respiratory disease (SMR= 3.52, 95% CI 1.98-5.78). Employing Cox’s proportional hazard modeling, postural instability and gait difficulty (PIGD) type and older age at onset predicted poor survival in this cohort.

Conclusions: This finding confirms the similar survival of patients with PD to the control population in the post-levodopa era. PIGD type and older age at onset had a negative impact on survival.

References: Raschetti R, Spila-Alegiani S, Vanacore N, et al. Mortality in a population-based cohort of patients treated with antiparkinsonian drugs. Acta Neurologica Scandinavica 1998;97(1):20-26. 2. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17(5):427-42. 3. Hely MA, Morris JG, Reid WG, et al. Sydney Multicenter Study of Parkinson’s disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005;20(2):190-9. doi: 10.1002/mds.20324 4. Hely MA, Morris JG, Traficante R, et al. The sydney multicentre study of Parkinson’s disease: progression and mortality at 10 years. J Neurol Neurosurg Psychiatry 1999;67(3):300-07. 5. Hely MA, Reid WG, Adena MA, et al. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord 2008;23(6):837-44. doi: 10.1002/mds.21956 6. de Lau LM, Verbaan D, Marinus J, et al. Survival in Parkinson’s disease. Relation with motor and non-motor features. Parkinsonism Relat Disord 2014;20(6):613-6. doi: 10.1016/j.parkreldis.2014.02.030 7. Wang G, Li XJ, Hu YS, et al. Mortality from Parkinson’s disease in China: Findings from a five-year follow up study in Shanghai. Can J Neurol Sci 2015;42(4):242-7. doi: 10.1017/cjn.2015.49. 8. Diem-Zangerl A, Seppi K, Oberaigner W, et al. Mortality in Parkinson’s disease, a 20-year follow-up study. Movement Disorders Official Journal of the Movement Disorder Society 2010;25(5):661. 9. Auyeung M, Tsoi TH, Mok V, et al. Ten year survival and outcomes in a prospective cohort of new onset Chinese Parkinson’s disease patients. J Neurol Neurosurg Psychiatry 2012;83(6):607-11. 10. Montastruc JL, Desboeuf K, Lapeyre-Mestre M, et al. Long-term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson’s disease. Mov Disord 2001;16(3):511-4. 11. Duarte J, García Olmos LM, Mendoza A, et al. The natural history of Parkinson’s disease in the province of Segovia: mortality in a longitudinal study (20-year follow-up). Acta Neurologica Scandinavica 2013;127(5):295–300. 12. Pinter B, Diem-Zangerl A, Wenning GK, et al. Mortality in Parkinson’s disease: a 38-year follow-up study. Mov Disord 2015;30(2):266-9. doi: 10.1002/mds.26060. 13. Hristova DR. Standardized mortality ratio and seasonal fluctuations of mortality in Parkinson’s disease. Folia Med (Plovdiv) 2009;51(2):40-5. 14. Ishihara LS, Cheesbrough A, Brayne C, et al. Estimated life expectancy of Parkinson’s patients compared with the UK population. Journal of Neurology Neurosurgery & Psychiatry 2007;78(12):1304. 15. Korell M, Tanner CM. Epidemiology of Parkinson’s disease: An overview. Journal of Geriatric Psychiatry & Neurology 2000;11(2):98-106. 16. Wang G, Hong Z, Cheng Q, et al. Validation of the Chinese non-motor symptoms scale for Parkinson’s disease: results from a Chinese pilot study. Clin Neurol Neurosurg 2009;111(6):523-6. doi: 10.1016/j.clineuro.2009.02.005. 17. Chen W, Chen S, Kang WY, et al. Application of odor identification test in Parkinson’s disease in China: a matched case-control study. J Neurol Sci 2012;316(1-2):47-50. doi: 10.1016/j.jns.2012.01.033. 18. Wang G, Cheng Q, Zheng R, et al. Economic burden of Parkinson’s disease in a developing country: a retrospective cost analysis in Shanghai, China. Mov Disord 2006;21(9):1439-43. doi: 10.1002/mds.20999. 19. Qiu P, Sheng J. A Two-Stage Procedure for Comparing Hazard Rate Functions. Journal of the Royal Statistical Society 2008;70(1):191–208. 20. Fall PA, Saleh A, Fredrickson M, et al. Survival time, mortality, and cause of death in elderly patients with Parkinson’s disease: a 9-year follow-up. Mov Disord 2003;18(11):1312–16. 21. Marras C, Mcdermott MP, Rochon PA, et al. Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohort. Neurology 2005;64(1):87-93.

« Back to 2018 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/mortality-from-parkinsons-disease-in-china-findings-from-a-ten-year-follow-up-study-in-shanghai/